India Large Volume Parenteral Market Size, Share & Trends Analysis Report By Volume, By Application (Therapeutic Injections, Fluid Balance Injections, Nutritious Injections), By End Use, And Segment Forecasts, 2018 - 2025

Industry Insights

The India large volume parenteral (LVP) market size was valued at USD 70.2 million in 2017 and is expected to exhibit a CAGR of 7.1% during the forecast period. The market is majorly driven by increased local manufacturing of LVP in the country, along with the growing prevalence of chronic diseases. 

The rising number of surgeries, the need for a faster route of drug administration, growing preference for single-dose administration of vaccines and drugs, and an increase in local manufacturing is expected to drive the market for LVP. Parenteral route of administration helps provide an accurate dose of medication as the majority of the drug is directly absorbed in circulation, bypassing the gastrointestinal tract.

The drug serum level increases rapidly through parenteral administration. For instance, postoperative parenteral nutrition induces a substantial increase in serum leptin within six hours and helps reach a rise of more than four folds within 14 hours. Moreover, parenteral administration of ascorbate (Vitamin C) decreases the growth rate of murine hepatoma. However, oral administration of the same dosage does not exhibit similar anti-tumoral effects.

The majority of LVP preparations are simple aqueous solutions requiring a simple manufacturing procedure since the solutes are easily soluble in water. Ongoing developments in health insurance and medical technology can also boost the pharma industry by eliminating financial and physical barriers to healthcare access in India.

Application Insights

The market is segmented on the basis of application into therapeutic injections, fluid balance injections, and nutritious injections. Of these, nutritious injections dominated the market in terms of revenue. LVP injections are used for either partial or total nutrition when oral intake is contraindicated. Earlier, these were used for patients requiring surgeries or those admitted in a hospital, but now, they are used as substitutes for nutrition obtained from a healthy diet.

The use of therapeutic injections is driven by a high incidence of cancer, HIV, and other life-threatening diseases that require a hospital stay. This has led to an increased number of surgeries and a rapid onset of action. A rise in the use of fluid balance injections can be observed particularly for new births.

Volume Insights

Based on volume, the India large volume parenteral (LVP) market is categorized into 100 ml, 250 ml, 500 ml, 1000 ml, and 2000 ml. Among these, 500 ml injectable held a majority market share in 2017, whereas the 100 ml injectable segment is expected to grow at a rapid rate over the forecast period.

Specific drugs exhibit therapeutic responses at a particular drug dose for the treatment of various conditions. For instance, paracetamol infusion of 100 ml is suggested for the treatment of fever or pain, especially post-surgery, when other means of administering medicines are not feasible. This dosage is specifically for patients weighing more than 50 kg and with no additional risk factors for hepatotoxicity. 

While the 250 mL 0.9% sodium chloride injection is usually used for treating isotonic extracellular dehydration as well as sodium depletion, 500 mL intravenous infusion of new hydroxyethyl starch solution (HES) 130/0.4 can be used to maintain cardiovascular stability during autologous blood donation in the preoperative stage. About 30,000 units of heparin in 0.9% solution of 1,000 mL sodium chloride is used in the prevention and treatment of blood clots, and a 2,000 mL dose of eporise is used for treating various conditions including cancer, major bone diseases, low hemoglobin, and HIV infection.

End-use Insights

Based on end use, the market is segmented into hospitals and other healthcare facilities and home care. Of these, hospitals and other healthcare facilities dominated the overall market in terms of revenue in 2017 and this trend is anticipated to continue in the coming years. Total Parenteral Nutrition (TPN) is an essential preparation for malnutrition, used in hospitalized patients where enteral feeding is not feasible or for critical care patients with compromised gastrointestinal tract function.

The Indian government has implemented policies to promote healthcare and increase its accessibility evenly in all parts of the country. For instance, in April 2018, the Ayushman Bharat scheme was launched by the country’s Prime Minister, providing coverage to 50 crore beneficiaries in secondary and tertiary care.

Healthcare at home is a developing market in the country owing to factors such as technology and demographics. According to a report published by India’s Ministry of Statistics and Program Implementation, in 2011, the country’s population census recorded 104 million elderly people over 60 years of age. This has resulted in increased demand for and availability of home care services that manage dose administration in the geriatric population.

India Large Volume Parenteral (LVP) Market Share Insights

Fresenius Kabi AG, Albert David Ltd., Baxter, Otsuka Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., B. Braun Melsungen AG, and BML Parenteral Drugs are some of the key market contributors. LVPs developed in India were not widely accepted since buyers were skeptical about the quality of products manufactured. However, as international pharmaceuticals such as Fresenius Kabi began sourcing LVPs from India for global marketing under their brand name, Indian parenteral solutions began gaining preference due to their cost advantage.

For instance, the oncology segment of Fresenius Kabi has manufacturing facilities at Baddi, Himachal Pradesh, and Kalyani, West Bengal. Moreover, Baxter’s manufacturing facility in Waluj, Maharashtra exclusively manufactures LVPs using state-of-the-art Form-Fill-Seal technology.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the India large volume parenteral (LVP) market report on the basis of application, volume, and end use:

• Application Outlook (Revenue, USD Million, 2014 - 2025)

  • Therapeutic Injections

  • Fluid Balance Injections

  • Nutritious Injections

• Volume Outlook (Revenue, USD Million, 2014 - 2025)

  • 100 ml

  • 250 ml

  • 500 ml

  • 1000 ml

  • 2000 ml

• End-use Outlook (Revenue, USD Million, 2014 - 2025)

  • Hospitals & Other Healthcare Facilities

  • Home Care